DelveInsight’s, “Ewing Sarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including Ewing Sarcoma clinical trials and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Ewing Sarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Ewing Sarcoma clinical trials studies, Ewing Sarcoma NDA approvals (if any), and product development activities comprising the technology, Ewing Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Ewing Sarcoma Pipeline Report

 

• DelveInsight’s Ewing Sarcoma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.

 

• The leading Ewing Sarcoma companies includes Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.

 

• Promising Ewing Sarcoma Companies includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

 

 

• The Ewing Sarcoma companies and academics are working to assess challenges and seek opportunities that could influence Ewing Sarcoma R&D. The Ewing Sarcoma pipeline therapies under development are focused on novel approaches to treat/improve Ewing Sarcoma.

 

To explore more information on the latest breakthroughs in the Ewing Sarcoma Pipeline treatment landscape of the report, click here @ Ewing Sarcoma Pipeline Outlook

 

Ewing Sarcoma Overview

Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis. Due to the considerable progress in the treatment of disease with both local therapy and multi-agent adjuvant chemotherapy, 5–year survival rate improved from less than 20% to greater than 70%, but the recurrence rate remains high.

 

Latest Developmental Activities or News of the Ewing Sarcoma Treatment Landscape

 

• In April 2022, AI Therapeutics announced the acquisition of EntreChem’s, investigational drug candidate EC-8042 (redesignated AIT-102), a novel targeted cancer therapy in development for rare pediatric and other cancers. AIT-102 specifically targets the mutations responsible for the formation and progression of two notable pediatric tumors, rhabdoid tumors and Ewing sarcoma, and holds the potential to treat a broader family of tumors that share a common mechanism of mutated or dysregulated SWI/SNF activity.

 

• In December 2021, Rakovina Therapeutics announced that it has been selected to join a three year US$975,000 (CDN$1,297,000) research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma.

 

For further information, refer to the detailed Ewing Sarcoma Unmet Needs, Ewing Sarcoma Market Drivers, and Ewing Sarcoma Market Barriers, click here for Ewing Sarcoma Ongoing Clinical Trial Analysis

 

Ewing Sarcoma Emerging Drugs Profile

 

Vigil: Gradalis

Gradalis is developing and testing Vigil, a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer. Vigil utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy with the goal to activate the patient’s own T-cells against their cancer cells. When those cells are reintroduced back into the patient, the two modifications are designed to help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation. All together, the goal is to stimulate the existing components of the immune system with the intent to improve their anti-tumor responses. Vigil enhances specific functions that assist in cancer antigen recognition and dampen other functions that cancer cells often employ to evade the immune system. A Phase III clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma (EWS) is currently ongoing.

 

ONCT216: Oncternal Therapeutics

ONCT-216 (formerly called TK216) is a first-in-class small molecule inhibiting the biological activity of ETS-family (E26 Transformation Specific) transcription factor oncoproteins in a variety of tumor types. It is currently being evaluated in the Phase II portion of a study in patients with relapsed or refractory Ewing sarcoma, a serious pediatric bone cancer. ONCT-216 was developed based on the discoveries of Jeff Toretsky, MD, at Georgetown University, who identified a small molecule that was shown to kill Ewing sarcoma cells and inhibit growth of tumors in preclinical studies. Oncternal scientists developed and tested a large series of derivatives of the research molecule and after extensive evaluation, ONCT-216 was selected as a lead product candidate. ONCT-216 has been extensively evaluated in preclinical studies, where it has been confirmed to kill Ewing sarcoma cells and inhibit Ewing sarcoma tumors in animal models. The company continues to collaborate with Dr. Toretsky and his colleagues in order to advance the research underlying the molecular pathways of ONCT-216 and optimize its development across multiple tumor types.

 

SP-2577: Salarius Pharmaceuticals

SP-2577 is being studied in an ongoing Phase I/II trial treating three different patient groups with sarcomas, including Ewing Sarcoma, Myxoid Liposarcoma and additional FET-rearranged soft tissue sarcomas. These are cancers with high-unmet need and represent Salarius’ “speed-to-market strategy” given the potential for accelerated approval. Salarius’ LSD1 technology was licensed from the University of Utah Huntsman Cancer Institute where it was developed in the laboratory of Dr. Sunil Sharma.

 

Ewing Sarcoma Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Ewing Sarcoma. The companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

 

Request a sample and discover the recent advances in Ewing Sarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Ewing Sarcoma Treatment Landscape

 

Scope of the Ewing Sarcoma Pipeline Report

 

• Coverage- Global
• Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.

 

• Ewing Sarcoma Companies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

 

• Ewing Sarcoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Ewing Sarcoma Market Drivers and Ewing Sarcoma Market Barriers, click here @ Ewing Sarcoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Ewing Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ewing Sarcoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Vigil: Gradalis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ONCT216: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SP-2577: Salarius Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. CLR 131: Cellectar Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ewing Sarcoma Key Companies
21. Ewing Sarcoma Key Products
22. Ewing Sarcoma- Unmet Needs
23. Ewing Sarcoma- Market Drivers and Barriers
24. Ewing Sarcoma- Future Perspectives and Conclusion
25. Ewing Sarcoma Analyst Views
26. Ewing Sarcoma Key Companies
27. Appendix

 

Got Queries? Find out the related information on Ewing Sarcoma Mergers and acquisitions, Ewing Sarcoma Licensing Activities @ Ewing Sarcoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services